Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Lim HF, Tan NS, Dehghan R, Shen M, Liew MF, Bee SWL, Sia YY, Liu J, Khor CC, Kwok I, Ng LG, Angeli V, Dorajoo R. Shortened Telomere Length in Sputum Cells of Bronchiectasis Patients is Associated with Dysfunctional Inflammatory Pathways. Lung 2022. [PMID: 35660961 DOI: 10.1007/s00408-022-00535-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 03/30/2022] [Indexed: 10/18/2022]

For:	Lim HF, Tan NS, Dehghan R, Shen M, Liew MF, Bee SWL, Sia YY, Liu J, Khor CC, Kwok I, Ng LG, Angeli V, Dorajoo R. Shortened Telomere Length in Sputum Cells of Bronchiectasis Patients is Associated with Dysfunctional Inflammatory Pathways. Lung 2022. [PMID: 35660961 DOI: 10.1007/s00408-022-00535-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 03/30/2022] [Indexed: 10/18/2022]

Number

Cited by Other Article(s)

Perea L, Bottier M, Cant E, Richardson H, Dicker AJ, Shuttleworth M, Giam YH, Abo-Leyah H, Finch S, Huang JTJ, Shteinberg M, Goeminne PC, Polverino E, Altenburg J, Blasi F, Welte T, Aliberti S, Sibila O, Chalmers JD, Shoemark A. Airway IL-1β is related to disease severity and mucociliary function in bronchiectasis. Eur Respir J 2024;64:2301966. [PMID: 38811046 DOI: 10.1183/13993003.01966-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 05/08/2024] [Indexed: 05/31/2024]

Abstract

RATIONALE

The inflammasome is a key regulatory complex of the inflammatory response leading to interleukin-1β (IL-1β) release and activation. IL-1β amplifies inflammatory responses and induces mucus secretion and hyperconcentration in other diseases. The role of IL-1β in bronchiectasis has not been investigated.

OBJECTIVES

To characterise the role of airway IL-1β in bronchiectasis, including the association with mucus properties, ciliary function, airway inflammation, microbiome and disease severity.

METHODS

Stable bronchiectasis patients were enrolled in an international cohort study (n=269). IL-1β was measured in sputum supernatant. A validation cohort also had sputum rheology and hydration measured (n=53). For analysis, patients were stratified according to the median value of IL-1β in the population (high versus low) to compare disease severity, airway infection, microbiome (16S rRNA sequencing), inflammation and caspase-1 activity. Primary human nasal epithelial cells grown in air-liquid interface culture were used to study the effect of IL-1β on cilia function.

RESULTS

Patients with high sputum IL-1β had more severe disease, increased caspase-1 activity and an increased T-helper type 1, T-helper type 2 and neutrophil inflammatory response compared with patients with low IL-1β. The active-dominant form of IL-1β was associated with increased disease severity. High IL-1β was related to higher relative abundance of Proteobacteria in the microbiome and increased mucus solid content and viscoelastic properties. Chronic IL-1β treatment reduced the functionality of cilia and tight junctions of epithelial cells in vitro.

CONCLUSIONS

A subset of stable bronchiectasis patients show increased airway IL-1β, suggesting pulmonary inflammasome activation is linked with more severe disease, airway infection, mucus dehydration and epithelial dysfunction.

Collapse

Affiliation(s)

Lidia Perea Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Mathieu Bottier Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, National Heart and Lung Institute, Imperial College London, London, UK
Erin Cant Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Hollian Richardson Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Alison J Dicker Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Morven Shuttleworth Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Yan Hui Giam Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Hani Abo-Leyah Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Simon Finch Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Jeffrey T-J Huang Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Michal Shteinberg Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel
Pieter C Goeminne AZNikolaas, Sint-Niklaas, Belgium
Eva Polverino Vall d'Hebron University Hospital, Barcelona, Spain
Josje Altenburg Amsterdam UMC, Amsterdam, The Netherlands
Francesco Blasi Department of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milan, Italy Department of Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
Tobias Welte Department of Respiratory Medicine, Medizinische Hochschule Hannover, Hannover, Germany
Stefano Aliberti Department of Biomedical Sciences, Humanitas University, Milan, Italy IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy
Oriol Sibila Respiratory Department, Hospital Clinic, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain
James D Chalmers Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK Senior authors contributed equally to this manuscript
Amelia Shoemark Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK Senior authors contributed equally to this manuscript

Collapse

Bertuccio FR, Baio N, Montini S, Ferroni V, Chino V, Pisanu L, Russo M, Giana I, Cascina A, Conio V, Grosso A, Gini E, Albicini F, Corsico AG, Stella GM. Potential New Inflammatory Markers in Bronchiectasis: A Literature Review. Curr Issues Mol Biol 2024;46:6675-6689. [PMID: 39057040 PMCID: PMC11275576 DOI: 10.3390/cimb46070398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2024] [Revised: 06/22/2024] [Accepted: 06/24/2024] [Indexed: 07/28/2024] Open

Affiliation(s)

Francesco Rocco Bertuccio Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Nicola Baio Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Simone Montini Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Valentina Ferroni Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Vittorio Chino Ospedale Pederzoli, Peschiera del Garda, 37121 Verona, Italy;
Lucrezia Pisanu Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Marianna Russo Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Ilaria Giana Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Alessandro Cascina Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Valentina Conio Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Amelia Grosso Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Erica Gini Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Federica Albicini Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Angelo Guido Corsico Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)
Giulia Maria Stella Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; (F.R.B.); (N.B.); (S.M.); (V.F.); (L.P.); (M.R.); (I.G.); (A.C.); (V.C.); (A.G.C.) Department of Internal Medicine and Pharmacology, University of Pavia, 27100 Pavia, Italy; (A.G.); (E.G.); (F.A.)

Collapse

Martins M, Keir HR, Chalmers JD. Endotypes in bronchiectasis: moving towards precision medicine. A narrative review. Pulmonology 2023;29:505-517. [PMID: 37030997 DOI: 10.1016/j.pulmoe.2023.03.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 03/10/2023] [Accepted: 03/13/2023] [Indexed: 04/09/2023] Open

Abstract

Bronchiectasis is a highly complex entity that can be very challenging to investigate and manage. Patients are diverse in their aetiology, symptoms, risk of complications and outcomes. "Endotypes"- subtypes of disease with distinct biological mechanisms, has been proposed as a means of better managing bronchiectasis. This review discusses the emerging field of endotyping in bronchiectasis. We searched PubMed and Google Scholar for randomized controlled trials (RCT), observational studies, systematic reviews and meta-analysis published from inception until October 2022, using the terms: "bronchiectasis", "endotypes", "biomarkers", "microbiome" and "inflammation". Exclusion criteria included commentaries and non-English language articles as well as case reports. Duplicate articles between databases were initially identified and appropriately excluded. Studies identified suggest that it is possible to classify bronchiectasis patients into multiple endotypes deriving from their co-morbidities or underlying causes to complex infective or inflammatory endotypes. Specific biomarkers closely related to a particular endotype might be used to determine response to treatment and prognosis. The most clearly defined examples of endotypes in bronchiectasis are the underlying causes such as immunodeficiency or allergic bronchopulmonary aspergillosis where the underlying causes are clearly related to a specific treatment. The heterogeneity of bronchiectasis extends, however, far beyond aetiology and it is now possible to identify subtypes of disease based on inflammatory mechanisms such airway neutrophil extracellular traps and eosinophilia. In future biomarkers of host response and infection, including the microbiome may be useful to guide treatments and to increase the success of randomized trials. Advances in the understanding the inflammatory pathways, microbiome, and genetics in bronchiectasis are key to move towards a personalized medicine in bronchiectasis.

Collapse

Baechle JJ, Chen N, Makhijani P, Winer S, Furman D, Winer DA. Chronic inflammation and the hallmarks of aging. Mol Metab 2023;74:101755. [PMID: 37329949 PMCID: PMC10359950 DOI: 10.1016/j.molmet.2023.101755] [Citation(s) in RCA: 111] [Impact Index Per Article: 55.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 05/30/2023] [Accepted: 06/13/2023] [Indexed: 06/19/2023] Open

Abstract

BACKGROUND

Recently, the hallmarks of aging were updated to include dysbiosis, disabled macroautophagy, and chronic inflammation. In particular, the low-grade chronic inflammation during aging, without overt infection, is defined as "inflammaging," which is associated with increased morbidity and mortality in the aging population. Emerging evidence suggests a bidirectional and cyclical relationship between chronic inflammation and the development of age-related conditions, such as cardiovascular diseases, neurodegeneration, cancer, and frailty. How the crosstalk between chronic inflammation and other hallmarks of aging underlies biological mechanisms of aging and age-related disease is thus of particular interest to the current geroscience research.

SCOPE OF REVIEW

This review integrates the cellular and molecular mechanisms of age-associated chronic inflammation with the other eleven hallmarks of aging. Extra discussion is dedicated to the hallmark of "altered nutrient sensing," given the scope of Molecular Metabolism. The deregulation of hallmark processes during aging disrupts the delicate balance between pro-inflammatory and anti-inflammatory signaling, leading to a persistent inflammatory state. The resultant chronic inflammation, in turn, further aggravates the dysfunction of each hallmark, thereby driving the progression of aging and age-related diseases.

MAIN CONCLUSIONS

The crosstalk between chronic inflammation and other hallmarks of aging results in a vicious cycle that exacerbates the decline in cellular functions and promotes aging. Understanding this complex interplay will provide new insights into the mechanisms of aging and the development of potential anti-aging interventions. Given their interconnectedness and ability to accentuate the primary elements of aging, drivers of chronic inflammation may be an ideal target with high translational potential to address the pathological conditions associated with aging.

Collapse

Dicpinigaitis PV. LUNG Year in Review: 2022. Lung 2023;201:1-4. [PMID: 36717405 PMCID: PMC9886218 DOI: 10.1007/s00408-022-00594-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/31/2022] [Indexed: 02/01/2023]